Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
reviparin
- Development stage
- Unknown
- Lead developer
- Abbott
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
Reviparin is a low molecular weight heparin (LMWH) anticoagulant derived from porcine intestinal mucosa by nitrous acid depolymerization. It has an average molecular weight of about 3.9 kDa and is characterized by a high anti-factor Xa to anti-factor IIa activity ratio. Reviparin acts by binding to antithrombin and catalyzing the inactivation of coagulation factors Xa and IIa (thrombin), thereby inhibiting the clotting cascade. It is primarily used for the prevention and treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), prophylaxis of perioperative thromboembolism, acute coronary syndrome, and prevention of acute thrombotic events after percutaneous transluminal coronary angioplasty (PTCA). Reviparin generally has a better safety profile than unfractionated heparin with fewer bleeding complications[2][3][5][7][9][10].
- Brand names
- ClivarinReviparine
- Other names
- reviparin sodiumClivarine
02
Targets
F2 (Thrombin)ATIII (Antithrombin III)F10 (Factor Xa)
Beyond the preview
Go deeper on reviparin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on reviparin.